test

STEAM (Sequencing Triplet with Avastin and Maintenance): Folfoxiri/Bevacizumab Regiments (Concurrent and Sequential) vs. Folfox/Bevacizumab in First-Line Metastatic Colorectal Cancer

Conditions

Colon

What is the purpose of this trial?

This randomized, open-label, multicenter study will evaluate the efficacy and safety of FOLFOXIRI/Avastin (bevacizumab) regimens (concurrent and sequential) versus FOLFOX/Avastin in first-line in patients with metastatic colorectal cancer. Patients will be randomized to receive Avastin 5 mg/kg intravenously every 2 weeks with either concurrent or sequential FOLFOXIRI or with FOLFOX for 4 to 6 months of induction therapy, followed by maintenance therapy with Avastin plus either leucovorin/5-fluorouracil or capecitabine until disease progression occurs. After disease progression, patients will receive treatment with a fluoropyrimidine-based chemotherapy plus Avastin.


Participation Guidelines

Age:
18 Years - 75 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Hoffman-La Roche
Dates:
07/30/2013
Last Updated:
Study HIC#:
1302011576